Iovance   Report issue

For profit Phase 1 Phase 2
Founded: New York NY United States (2007)

Organization Overview

First Clinical Trial
2012
NCT01701674
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Iovance Biotherapeutics | Iovance Biotherapeutics, Inc. | Lion Biotechnologies | Lion Biotechnologies, Inc.